



Press Release

April 2, 2019

Strides to launch Potassium Chloride Extended-Release Tablets in the US market

**Product jointly developed with Pharmaceuticals International, Inc.
To be commercialized by Strides in the US market**

Bangalore, April 2, 2019 Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Vensun Pharmaceuticals, Inc., USA and its partner Pharmaceuticals International, Inc. (Pii) have received approval for jointly developed **Potassium Chloride Extended-Release Tablets USP, 10 mEq (750 mg), 15 mEq (1,125 mg), and 20 mEq (1,500 mg)** product from the United States Food & Drug Administration (US FDA). The product is an immediately dispersing extended-release oral dosage form of potassium chloride and is a generic version of Potassium Chloride Extended-Release Tablets of Merck, Inc.

According to IQVIA MAT data, the US market for Potassium Chloride Extended Release Tablets with the current reference product is approximately US\$ 240 Mn. The product will be manufactured by Pii and will be marketed by Strides in the US market. Strides already has an approval for Potassium Chloride Extended Release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg) which is a generic version of Klor-Con Extended Release Tablets of Upsher-Smith. The two approvals taken together will help company address a combined opportunity of US\$ 300 Mn per annum, representing ~ 90% of the Potassium Chloride Extended Release tablet market in the US.

About Potassium Chloride Extended-Release Tablet

Potassium Chloride Extended-Release Tablet is an electrolyte replenisher and is used in treatment of patients with hypokalemia. It is prescribed to slow the release of potassium so that the likelihood of a high localized concentration of potassium chloride within the gastrointestinal tract is reduced. Extended release tablet is formulated in such a way that the drug is released slowly over time. This has the advantage of taking pills less often and fewer side effects, as the levels of the drug in the body are more consistent.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor - funded markets. The Company's global manufacturing sites are located in India - Bangalore (two sites), Pondicherry and Chennai, Singapore, Italy - Milan and Kenya - Nairobi.

The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

About Pharmaceuticals International, Inc. (Pii)

Pii is a privately held CDMO providing dosage form development and cGMP manufacturing services to the global pharmaceutical industry. Headquartered in Hunt Valley, Maryland USA, Pii's services include pre-formulation development, and clinical and commercial cGMP manufacturing of parenterals, liquid solutions and oral solids, including soft gels, tablets and capsules. In addition, the Company offers containment suites to handle potent drugs and Schedules I-V controlled substances.

For further information, please contact:

<p><u>Strides</u> Badree Komandur, Executive Director - Finance +91 80 6784 0747</p> <p><u>Investor Relations</u> Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791 Email: Sandeep.baid@strides.com</p> <p><u>Strides Pharma Science Limited</u> (Formerly Strides Shasun Limited) CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi Mumbai - 400 703 Corp. Office: Strides House, Bannerghatta Road, Bangalore - 560076</p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 90005 27213 srinivas@fortunapr.com</p> <p>K Priya: +91 95354 25418 priya@fortunapr.com</p>
--	---